Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


The Company’s current investors include:

Abingworth Management

Cancer Research Technology

Essex Woodlands Healthcare Ventures

Gilde Investment Management


Phase4 Partners

The Institute of Cancer Research

The University of Cambridge

The Wellcome Trust

Latest News

Tosedostat Opal Study In Acute Myeloid Leukaemia Published In Lancet Oncology

Chroma Therapeutics Advances Novel Targeted Agent Towards Clinical Development; Receives Milestone Payment And Extends Collaboration With GSK

Featured Programme
Cell Accumulation Approach